CMT&Me is an observational, non-interventional study, sponsored by Pharnext, to collect Real-World Evidence (RWE) from people living with CMT. The objective of the study is to better understand the impact of the disease on patients’ daily lives: the burden of CMT, its natural history and treatment, and medical, social and pharmacoeconomic effects.
Mark your calendars for April 24–26, 2025, because the Nashville CMT Summit is bringing the...
On March 19th, at the MDA Clinical and Scientific Conference in Dallas, TX, Dr. Cornett will...
CMT Summit + Retreat 2025: Uniting Patients, Researchers, Regulators, and Industry Leaders to...
CMT Simplified is here to make staying informed about Charcot-Marie-Tooth disease (CMT) easier...
NMD670, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA)
Join the thousands of HNF volunteers who are fueling CMT research. The more you share, the more we’ll learn. Complete your GRIN surveys today!
HNF Awards the inaugural HNF Clinical Translation Fellowship in the amount of $170,000 to Kayla...
The INSPIRE trial is a Phase 3 double-blind placebo-controlled registrational study evaluating the effect of once-daily (QD) oral govorestat (AT-007) in 56 patients aged 16-55 with SORD Deficiency in the US and Europe.
HNF Contributes CMTRN Data to C-Path’s RDCA-DAP, Strengthening Research Capabilities for Inherited...
HNF is thrilled to announce that we have been accepted to host a 1-hour panel discussion during the Bio International Convention in San Diego, CA, in June 2024.
0 Comments